Live from the registry
Clinical trials
Live from the ClinicalTrials.gov registry. Registration is not endorsement: a registered trial may be small, early, or studying a single age-associated condition rather than ageing itself. Always read the registry entry before drawing conclusions.
Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma
completedBroto, Javier Martín, M.D. · PHASE2 · 33 participants
Primary outcome measured: Progression free survival (PFS) rate
Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
recruitingMiller Children's & Women's Hospital Long Beach · EARLY_PHASE1 · 20 participants
Primary outcome measured: 5 year Event Free Survival
Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF
unknownInstitut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · PHASE4 · 5 participants
Primary outcome measured: Change in calcineurin & mTOR inhibitors' blood concentrations after switch to B/F/TAF
Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients
terminatedM.D. Anderson Cancer Center · PHASE1, PHASE2 · 44 participants
Primary outcome measured: Tumor Response
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy
unknownChao Huang · PHASE1 · 15 participants
Primary outcome measured: Incidence of treatment-emergent adverse events.
Biology Guided Therapy for Breast Cancer for ER Positive
terminatedInova Health Care Services · PHASE2 · 2 participants
Primary outcome measured: Progression Free Survival
Belatacept to Prevent Organ Rejection in Kidney Transplant Patients
terminatedNational Institute of Allergy and Infectious Diseases (NIAID) · PHASE2 · 5 participants
Primary outcome measured: Acute Rejection at 6-Months
Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder
recruitingOHSU Knight Cancer Institute · PHASE1 · 6 participants
Primary outcome measured: Incidence of grade 3+ treatment-related adverse events (TRAEs)
Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast
terminatedStanford University · PHASE1 · 18 participants
Primary outcome measured: Using three cohorts of patients with fixed dosing of capecitabine in combination with increasing doses of RAD001, the maximum tolerated doses and toxicities will be determined.
Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease
completedStanford University · PHASE2 · 36 participants
Primary outcome measured: Clinical Activity
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
active not recruitingNational Cancer Institute (NCI) · PHASE2 · 1,377 participants
Primary outcome measured: Proportion of Pediatric Patients Whose Advanced Tumors Have Pathway Alterations That Can be Targeted by Select Anti-cancer Drugs
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
completedMayo Clinic · EARLY_PHASE1 · 2 participants
Primary outcome measured: Proportion of confirmed responses, evaluated using the RECIST v1.1
Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal
completedUniversity at Buffalo · PHASE4 · 58 participants
Primary outcome measured: Number of Participants With Graft Survival at 12 Months
Phase II Study of Alternating Sunitinib and Temsirolimus
completedDartmouth-Hitchcock Medical Center · PHASE2 · 37 participants
Primary outcome measured: Progression Free Survival
Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension
completedAadi Bioscience, Inc. · PHASE1 · 15 participants
Primary outcome measured: Dose-limiting Toxicities
NCT Neuro Master Match - N²M² (NOA-20)
completedUniversity Hospital Heidelberg · PHASE1, PHASE2 · 228 participants
Primary outcome measured: PFS-6 rate
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
completedFox Chase Cancer Center · PHASE1 · 12 participants
Primary outcome measured: Number of patients with dose limiting toxicity
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
completedRoswell Park Cancer Institute · PHASE1 · 7 participants
Primary outcome measured: Safety of ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine in combination with varying dose levels and schedules of sirolimus, assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
completedSt. Jude Children's Research Hospital · PHASE1 · 23 participants
Primary outcome measured: Feasibility of haploidentical HSCT
Rapamycin+Estradiol- vs. Rapamycin-Eluting Stents to Reduce Restenosis (ISAR-PEACE)
completedDeutsches Herzzentrum Muenchen · PHASE4 · 502 participants
Primary outcome measured: in-stent late luminal loss
Source: ClinicalTrials.gov API v2, retrieved live and cached for one hour. Longevity Record is not affiliated with ClinicalTrials.gov or the US National Library of Medicine. Trial participation is a medical decision — see our disclaimer.